Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4771MR)

This product GTTS-WQ4771MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4771MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5854MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ15978MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ2118MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ9075MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ13117MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ4437MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ1477MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW